Safety And Efficacy Of Once Weekly Basal Insulin Fc In People With Type Basal insulin fc (bif, insulin efsitora alfa), designed for once weekly administration, is a fusion protein combining a novel single chain insulin variant with a human immunoglobulin g (igg) fc domain. in this study, we explored the safety and efficacy of bif in people with type 2 diabetes who had been previously treated with basal insulin. The burden of daily basal insulins often causes hesitancy and delays in the initiation of insulin therapy. basal insulin fc (bif, insulin efsitora alfa), designed for once weekly administration, is a fusion protein combining a novel single chain insulin variant with a human immunoglobulin g (igg) fc domain.
Underline Once Weekly Basal Insulin Fc Bif Is Safe And Efficacio For people with t1d treated with multiple daily basal injections, a once weekly basal insulin would lead to the reduction from 365 basal insulin injections to 52 over the course of a year. basal insulin fc (bif; ly3209590, insulin efsitora alfa) is a fusion protein combining a novel single chain insulin variant with a human igg2 fc domain and. Two once weekly basal insulins are currently under clinical development: basal insulin fc (bif) (insulin efsitora alfa; ly3209590) and insulin icodec. bif is a fusion protein combining a novel single chain insulin variant together with a human igg 2 fc domain and is designed for once weekly subcutaneous administration. This is the first treat to target, basal switch study comparing the efficacy and safety of bif with insulin degludec in people with type 2 diabetes who had been previously treated with basal insulin. treatment with bif for 32 weeks resulted in improvement in glycaemic control compared to baseline as measured by change in hba 1c (primary outcome). Request pdf | safety and efficacy of once weekly basal insulin fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open label, randomised, phase 2 study.
Comments are closed.